You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
TOKYO, July 11, 2014 /PRNewswire/ -- Astellas today announced progress on the Company's efforts to reshape its research framework at its R&D meeting held in Tokyo on July 10. The meeting provided an opportunity for Astellas to present a comprehensive overview of its late-stage clinical programs and corporate strategy. The purpose of the meeting was to provide an update on the initiatives for Astellas innovation, drug discovery research and pipeline progress.
Yoshihiko Hatanaka, president and CEO, opened the meeting by discussing how Astellas will continue to drive sustainable growth through maximizing the value of product portfolio, pursuing operational excellence and enhancing innovation through reshaping the company's research framework, and developing network research systems by more utilizing external resources. The full presentation, including details of the corporate strategy can be found in the webcast available here: http://www.astellas.com/en/ir/library/presentation_02.html.
Sef Kurstjens, M.D., Ph.D., chief medical officer, provided a development overview of the following compounds:
In May 2013, Astellas formed a strategic alliance with Amgen to develop and commercialize five Amgen pipeline medicines in Japan. Development updates for three of those products were also highlighted at the meeting, including rilotumumab (AMG 102) for gastric cancer, evolocumab (AMG 145) for hyperlipidemia, and romosozumab (AMG 785) for osteoporosis.
"Astellas has a long track record of delivering value to shareholders through efficient investment in R&D. This investment has provided several important new treatment options that have helped to meet patients' unmet medical needs," said Kurstjens. "As a result of our efforts, we have established Global Category Leadership positions in urology and transplantation and an emerging GCL position in oncology. We're pleased with our pipeline progress in these therapeutic categories and are excited about our future prospects to expand our R&D efforts to explore additional areas of unmet medical needs."
Wataru Uchida, Ph.D., senior vice president, drug discovery research, discussed our research initiatives and provided details of potential new therapeutic areas that Astellas is pursuing, as well as novel technology platforms that the company is utilizing, including ClearPath, ADC and regenerative medicine. In addition, Uchida discussed the preclinical research achievements for ASP2215, a potential treatment for leukemia, and ASP8273, a potential treatment for non-small cell lung cancer patients with EGFR mutations.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The headquarters for the Americas is located in Northbrook, Ill. For more information on Astellas, please visit our website at www.astellas.us.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.